Contribution of Diagnostic Tests and Drug Therapy in Screening of Benign Prostatic Hyperplasia (BPH) in Western

Abstract The incidence of benign prostatic hyperplasia (BPH) is known through the American and European continents whereas it remains much to make to know the epidemiologic profile of this pathology in Algeria. This study aims to show a contribution of diagnostic tests and drug therapy in screening of BPH in Western Algerian hospital. Our study was carried out on 385 men recruited in the Urology department of Saida hospital during the period 2010-2013, consulting for urologic problems whose 120 patients, aged between 45-84 years, have BPH. BPH frequency was 31.1 %. It was prevalent in the age -specific range of 65-74 years. The physical, biological and histological examinations revealed that 75 % of the patients were diagnosed by digital rectal examination (DRE), 70 % have serum-TPSA level lower than 4 ng/ml and 71.2 % have a histological type named "prostatic hyperplasia adeno-fibro-Leio myomatic (or PHAFLM)". As for an assumption of responsibility concerning BPH patients 52.7 % have chosen a medical treatment. This work showed the proportion of the subjects carrying BPH in this area of Algeria. This study provides information on the incidence of BPH in this area of Algeria. But more work needs to come to reinforce the results to uncover the various risk factors (age, race, diet, hormones) that are behind the development of this disease. Keywords: Incidence; benign prostatic hyperplasia; urology; TPSA. Introduction Benign prostatic hyperplasia (BPH) is a common urological disease in older men. BPH, known as nodular hyperplasia, is a disease characterized by histological changes in the prostate glan